A high-throughput platform for the non-invasive intracellular delivery of molecules for therapeutic applications

  • WO2020257746
    :
    Isolating live cells after high-throughput, long-term, time-lapse microscopy
    (Patent application)

A natural beta interferon-inducing therapeutic glycolipid from the microbiome that prevents and treats severe viral infection

  • WO2021257494
    :
    Methods for modulating TLR4 signaling
    (Patent application)

A novel biologic and therapeutic target for the treatment of diabetes

  • WO2020061591
    :
    Secreted protein that affects blood glucose levels
    (Patent application)

Application of the SPLANDID antigen presentation technology to HIV-1 vaccine development

  • WO2020139963
    :
    Membrane protein nanoparticles for antigen presentation
    (Patent application)

Assessment of targeted protein degradation as a strategy for potent antivirals with high barriers to resistance

  • WO2020069125
    :
    Degraders of Hepatitus C Virus NS3/4A Protein
    (Patent application)

Building better screens and identifying ligands for human MS4A proteins

  • WO2017143036
    :
    Identification of the MS4A family as ligand-gated ion channels
    (Abandoned)

Computationally designed therapy targeting lysosomal function and inflammation in neurodegenerative diseases

  • WO2020191212
    :
    Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
    (Patent application)

Developing novel therapeutic approaches for CNS drug delivery by targeting a newly identified key regulator of the blood brain barrier

  • WO2014205338
    :
    Methods and compositions relating to modulation of the permeability of the blood brain barrier
    (Abandoned)
  • WO2022155410
    :
    Structure and mechanisms of the blood-brain barrier DHA transporter Mfsd2a
    (Patent application)
  • WO2023225249
    :
    Modulation of the Permeability of the Blood Brain Barrier
    (Patent application)

Development of AAV-mediated mini-gene therapy for Usher syndrome type 1F, a combined deafness and blindness

  • WO2020219990
    :
    Mini-PCDH15 for treatment of deafness and blindness
    (Patent application)

Development of an inexpensive at-home influenza kit and detection technology

  • WO2021195023
    :
    Enhancement of RT-RPA reaction by the addition of RNaseH
    (Abandoned)
  • WO2021202158
    :
    Development of an inexpensive at-home influenza
    (Abandoned)

Development of small molecule modulators of autophagy and ER stress as novel therapeutics for AD

  • WO2021257697
    :
    Compounds and methods for blocking apoptosis and inducing autophagy
    (Patent application)

Development of synthetic analogs of a sleeve gastrectomy-induced metabolite as a novel therapy for type 2 diabetes and obesity

  • WO2020041673
    :
    Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
    (Patent application)
  • WO2021226447
    :
    Methods for inducing bile acid sulfotransferase SULT2A for treating metabolic disorders
    (Patent application)
  • WO2020117945
    :
    Synthetic derivatives of cholic acid 7-sulfate and uses thereof
    (Patent application)

Engineered proteins for treatment of pancreatitis

Gene therapy for the treatment of Wolfram Syndrome II

  • WO2021222476
    :
    DAEUS: a high effciency gene delivery system for overexpression of geroprotective genes
    (Patent application)

Identifying novel therapeutic targets for treating pain and chronic itch

  • US20210356455A1
    :
    G-protein-coupled receptors (GPCRs) regulating; somatosensation from single-cell transcriptome atlas
    (Patent application)

Isoguvacine and benzodiazepine derivatives for the treatment of tactile hypersensitivity and anxiety in autism spectrum disorders

  • WO2017214442
    :
    Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome
    (Patent application)
  • WO2019232046
    :
    Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
    (Patent application)
  • WO2019226808
    :
    Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
    (Patent application)
  • WO2020198275
    :
    Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
    (Patent application)
  • WO2020237043
    :
    Human tactile prepulse inhibition assay
    (Patent application)

Manipulating mitobiogenesis by targeting ME2

  • WO2022197978
    :
    Compositions and Methods for Modulating Mitochondrial Function and Biogenesis
    (Abandoned)

Multiplex editing the human genome

  • WO2020180975
    :
    Highly multipexed genome editing
    (Patent application)

Next-generation AAV therapies for management of intractable chronic pain

  • WO2020118012
    :
    A scalable platform for the development of cell-type-specific viruses
    (Patent application)
  • WO2023092055
    :
    Nociceptor-specific gene regulatory elements for the treatment of pain
    (Patent application)

Small molecule modulators of gut bacterial bile acid metabolism to treat metabolic syndrome and associated non-alcoholic fatty liver disease (NAFLD)

  • WO2020231776
    :
    Small molecule modulators of gut bacterial bile acid metabolism
    (Patent application)

Targeting neuro-immune signaling to treat bacterial infections

  • WO2018236873
    :
    Methods and compositions for treating a microbial infection
    (Patent application)